Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Recombinant Erythropoietin in Plasma Levels of FGF23 in End-Stage Renal Disease Patients

NCT03803514 is registered in ClinicalTrials.gov with University of Chile as lead sponsor.

NCT NCT03803514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03803514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Recombinant Erythropoietin in Plasma Levels of FGF23 in End-Stage Renal Disease Patients
Lead sponsor
University of Chile
Phase
Observational
Overall status
Completed
Start date
August 15, 2017
Completion date
October 20, 2019
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, chronic kidney diseases